FDA Inspection
LGM Pharma Solutions, LLCLGM Pharma Solutions, LLC – FDA Inspection, Mar 1, 2024
Record Details
This FDA Inspection record concerns LGM Pharma Solutions, LLC, with an inspection on March 1, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 1d4efc76-d6cb-4820-a2a8-d28f1e3bc96a
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1230374
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
4- 21 CFR 211.160(a)Deviations from laboratory control requirements
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.67(b)Written procedures not established/followed
- 21 CFR 211.100(a)Absence of Written Procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of LGM Pharma Solutions, LLC
13| Date | Classification | Office | Project area |
|---|---|---|---|
| May 18, 2026 | Not classified | Los Angeles District Office | Drug Quality Assurance |
| January 24, 2025 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| January 31, 2020 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| August 17, 2018 | VAI | Center for Drug Evaluation and Research | Postmarket Surv. and Epidemiology |
| October 20, 2017 | Not classified | Los Angeles District Office | Generic Drug Evaluation |
Other documents for LGM Pharma Solutions, LLC
- FDA Inspection 1317740 - 2026-05-18
- FDA Inspection 1232056 - 2025-01-24
- FDA Inspection 1120565 - 2020-01-31
- FDA Inspection 1062404 - 2018-08-17
- FDA Inspection 1029466 - 2017-10-20
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.